Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
86925 trials found · Page 91 of 4347
-
Scientists unleash engineered immune cells and Cancer-Killing virus in First-of-Its-Kind trial
Disease control Recruiting nowThis study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Apr 08, 2026 12:03 UTC
-
Electric field therapy shows promise in brain cancer battle
Disease control CompletedTo test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following…
Phase: NA • Sponsor: NovoCure Ltd. • Aim: Disease control
Last updated Apr 24, 2026 16:07 UTC
-
New Bladder-Sparing cancer treatment enters final testing phase
Disease control OngoingThe purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 06, 2026 14:17 UTC
-
One-Shot gene injection aims to halt blindness in rare eye disease
Disease control CompletedA clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New hope for kids with tough brain tumors: scientists test 'Living Drug'
Disease control Recruiting nowThis phase I trial investigates the side effects of chemotherapy and cellular immunotherapy in treating children with IL13Ralpha2 positive brain tumors that have come back after a period of improvement (recurrent) or do not respond to treatment (refractory). Cellular immunotherap…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
Chinese COVID vaccine trial shows strong immune response
⭐️ VACCINE ⭐️ CompletedThis was a phase II, randomized, placebo-controlled, observer-blinded study of the safety and immunogenicity of SARS-CoV-2 messenger RNA (mRNA) vaccine (BNT162b2) in Chinese healthy population. After randomization, the trial for each participant lasted for approximately 13 months…
Phase: PHASE2 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 26, 2026 19:39 UTC
-
Immune cell therapy shows promise for aggressive blood cancer
Disease control Recruiting nowA Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC
-
Double-Punch cancer treatment shows promise in early trials
Disease control OngoingThis phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axicabtagene ciloleucel is enginee…
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
New hope for hard-to-treat lung cancer: targeted combo therapy enters late-stage trial
Disease control Recruiting nowThe Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 port…
Phase: PHASE2, PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:42 UTC
-
Lifesaving cord blood transplants tested for kids without matched donors
Disease control Recruiting nowThis is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 16, 2026 13:02 UTC
-
One-Shot gene therapy could free patients from monthly eye injections
Disease control OngoingABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without Center-Involved Diabetic Macular Edema (CI-DME). DR is a chronic and progressive complication of diabetes mellitus. It is a sight-…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 13, 2026 20:17 UTC
-
Stomach cancer patients may get a powerful new treatment option
Disease control OngoingThis is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 26, 2026 19:39 UTC
-
Polio virus weaponized to fight tough skin cancer
Disease control CompletedA Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibitor.
Phase: PHASE2 • Sponsor: Istari Oncology, Inc. • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC
-
Brain bleed breakthrough? new surgery could change stroke care
Disease control Recruiting nowA randomized controlled trial of ultra-early, minimally invasive, hematoma evacuation versus standard care within 8 hours of intracerebral hemorrhage. Patients presenting to the emergency department with stroke due to supratentorial, spontaneous intracerebral hemorrhage \>20mL vo…
Phase: NA • Sponsor: University of Melbourne • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC
-
Cheek cells offer new hope for the blind
Disease control Recruiting nowSome severe ocular burns or other rare ocular pathologies can be associated with a total loss of corneal epithelial stem cells (i.e. Limbal Stem Cell Deficiency - LSCD), which leads to cornea invasion by the conjunctiva and a subsequent opacification. When LSCD is total and bilat…
Phase: PHASE1, PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
Cord blood boost: new treatment shows promise for tough leukemia cases
Disease control CompletedCord blood (CB) transplants are an option for patients lacking an HLA identical donor but are hampered by low cell dose, prolonged aplasia and high transplant related mortality. UM171, a novel and potent agonist of hematopoietic stem cell self renewal could solve this major limit…
Phase: PHASE2 • Sponsor: ExCellThera inc. • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC
-
New valve replacement offers hope for heart patients with no other options
Disease control Recruiting nowThis study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollmen…
Phase: NA • Sponsor: Edwards Lifesciences • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC
-
New 'Living Drug' trial aims to Re-Train immune cells to hunt down blood cancers
Disease control Recruiting nowThis study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the kappa light chain antibody on c…
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC
-
Pfizer tests drug to protect Kids' brains from sickle cell damage
Disease control TerminatedThis study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to \< 15 years old, with Sickle Cell Disease. The primary objective is to evaluate the effect of voxelotor on the TCD (Transcranial Doppler Ultrasound) mea…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
One-Shot gene therapy tested to halt debilitating protein disease
Disease control CompletedThis study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NTLA-2001 in participants with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and participants with hereditary transthyretin amyloidosis wit…
Phase: PHASE1 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC